Individualised drug therapy based on pharmacogenomics: focus on carboxylesterase 1 (CES1) Individuelle forskelle i omsætningen af lægemidler

Trial Profile

Individualised drug therapy based on pharmacogenomics: focus on carboxylesterase 1 (CES1) Individuelle forskelle i omsætningen af lægemidler

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 21 Sep 2013

At a glance

  • Drugs Methylphenidate (Primary) ; Trandolapril (Primary) ; Enalapril
  • Indications Atherosclerosis; Attention-deficit hyperactivity disorder; Heart failure; Hypertension; Myocardial infarction
  • Focus Pharmacogenomic; Pharmacokinetics
  • Acronyms INDICES-WP2
  • Most Recent Events

    • 21 Sep 2013 Planned number of patients changed from 35 to 45 as reported by European Clinical Trials Database record.
    • 08 Dec 2012 Additional drug 'enalapril' added as treatment arm as reported by European Clinical Trials Database record.
    • 27 Feb 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top